Published in final edited form as:

Mol Cancer Ther. 2010 October ; 9(10): 2700–2713. doi:10.1158/1535-7163.MCT-10-0645.

Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability

Emin Oroudjev¹, Manu Lopus¹, Leslie Wilson¹, Charlene Audette², Carmela Provenzano², Hans Erickson², Yelena Kovtun², Ravi Chari², and Mary Ann Jordan¹

¹ Department of Molecular, Cellular, and Developmental Biology, and the Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara CA 93106

² ImmunoGen, Inc., 830 Winter Street, Waltham, MA 02451

Abstract

Maytansine and its analogs (maytansinoids) are potent microtubule-targeted compounds that inhibit proliferation of cells at mitosis. Antibody-maytansinoid conjugates consisting of maytansinoids (DM1 and DM4) attached to tumor-specific antibodies have shown promising clinical results. To determine the mechanism by which the antibody-DM1 conjugates inhibit cell proliferation, we examined the effects of the cleavable anti-EpCAM -SPP-DM1 and uncleavable anti-EpCAM-SMCC-DM1 conjugates on MCF7 human breast tumor cells. We also examined the effects of the free maytansinoids, maytansine and *S*-methyl DM1 (a version of DM1 that is stable in cell culture medium) for comparison. Both the conjugates and free maytansinoids potently inhibited MCF7 cell proliferation at nanomolar and subnanomolar concentrations, respectively, by arresting the cells in mitotic prometaphase/metaphase. Arrest occurred in concert with the internalization and intracellular processing of both conjugates under conditions that induced abnormal spindle organization and suppressed microtubule dynamic instability. Microtubule depolymerization occurred only at significantly higher drug concentrations. The results indicate that free maytansinoids, antibody-maytansinoid conjugates, and their metabolites exert their potent antimitotic effects via a common mechanism involving suppression of microtubule dynamic instability.

Keywords

maytansine; DM1; antibody-drug conjugate; microtubules; dynamic instability

Introduction

Maytansine and its analogs (Fig. 1) are benzoansamamides (1–3) that demonstrate powerful anti-mitotic activity (4,5). Maytansine (Fig. 1) is a microtubule-targeted drug that binds to tubulin at the vinca binding site (6,7) and, similar to vinca alkaloids, it can depolymerize microtubules and arrest cells in mitosis (8–10). Maytansine displays almost 100 times higher cytotoxicity in cells than the vinca alkaloids (11).

In human clinical trials, maytansine demonstrated a small therapeutic window due to neurotoxicity and to adverse effects on the gastrointestinal tract (11). However, the powerful cytotoxicity of maytansinoids could make them valuable for anti-cancer therapies employing

tissue-specific drug delivery approaches, particularly as antibody-maytansinoid-conjugates (AMCs) (12–16). Preclinical studies indicate that AMCs have significantly improved potential as anti-cancer agents as compared to the unconjugated maytansinoids (17–19). Clinical trials employing several different AMCs have been conducted (20–22) and a recent trial of trastuzumab-DM1 (T-DM1), a maytansinoid conjugated to the anti-HER2 therapeutic antibody trastuzumab, showed good efficacy in metastatic breast cancer (23) and the CD-56 targeting-AMC, lorvotuzumab-mertansine has shown promising results in solid and liquid tumors that express CD56 (24). T-DM1 (trastuzumab-MCC-DM1) utilizes a non-reducible thioether-based linker, while lorvotuzumab mertansine (huN901-SPP-DM1) utilizes a disulfide-based linker (Fig. 1).

The optimal linker for an AMC is selected by preparing conjugates with a panel of linkers and evaluating their activity *in vitro* and in human tumor xenograft models. The conjugate with the most anti-tumor activity and the widest therapeutic window as defined by the difference between the maximum tolerated dose and minimally effective dose is then selected. Preclinical studies (25,26) with anti-CanAg (tumor-associated protein CA242)-targeting AMCs showed that the huC242 antibody component of cleavable disulfide-linked huC242-SPP-DM1 and the uncleavable huC242-SMCC-DM1 conjugate is proteolytically degraded in targeted cancer cells following antigen-mediated internalization and vesicular trafficking to the lysosomes to yield lysine-SPP-DM1 and lysine-SMCC-DM1 metabolites, respectively. The lysine-SPP-DM1 derived from the disulfide linked conjugate undergoes further intracellular reduction to yield DM1 (25,26). Formation of the hydrophobic DM1 metabolite is proposed to explain the bystander cell killing activity of huC242-SPP-DM1 that was observed in human tumor xenograft models (19). Microtubules are polymers composed of the protein tubulin that play a major role in mitosis and other important cell functions (27). Microtubules are highly dynamic polymers and their dynamics are tightly controlled both spatially and temporally in cells. In one type of dynamics, dynamic instability, the ends of microtubules alternate between phases of growth and shortening. Recent research shows that many microtubule-targeted compounds, including the vinca alkaloids, suppress dynamic instability, and they do so at concentrations significantly lower than those required to depolymerize microtubules. Suppression of dynamic instability plays a major role in the anti-mitotic effects of these drugs (27–29).

In an accompanying paper we report that maytansine and *S*-methyl DM1 (DM1-Me) bind to soluble tubulin with similar affinities (K_D 's of 0.86 $\mu\text{mol/L}$ and 0.93 $\mu\text{mol/L}$, respectively), and that they inhibit microtubule polymerization with similar potencies (IC_{50} 's of 1 $\mu\text{mol/L}$ and 4 $\mu\text{mol/L}$, respectively). Using purified bovine brain microtubules *in vitro*, we found that at a concentration of 100 nM, the maytansinoids suppress dynamic instability by binding with high affinity to a small number of sites at microtubule ends (30). For example, we found that *S*-methyl DM1 binds to 37 saturable sites on microtubules with a K_D of $0.1 \pm 0.05 \mu\text{mol/L}$ and to a large number of low affinity sites on microtubules and sedimentable aggregates with a K_D of $2.2 \pm 0.2 \mu\text{mol/L}$. Thus their affinity for tubulin at microtubule ends is 20-fold stronger than their affinity for free tubulin.

To understand the mechanism of action of the antibody-conjugated maytansinoids, we investigated the concentration- and time-dependent effects of maytansine, *S*-methyl DM1, and anti-EpCAM-DM1 conjugates on proliferation, G2/M arrest, microtubule organization, and dynamic instability in MCF7 cells. Although antibody-DM1 conjugates are prepared with the thiol-containing maytansinoid DM1, we found that DM1 can oxidize in aqueous solution to give DM1 disulfide dimer or undergo disulfide exchange with cysteine in cell culture media to give a mixed disulfide. Thus, we used the stable DM1 methyl thioether derivative (*S*-methyl DM1) in these studies. We found that the antibody-DM1 conjugates, maytansine, *S*-methyl DM1, and the intracellular metabolites of the antibody-DM1 conjugates all inhibit proliferation and induce mitotic arrest in association with suppression of microtubule dynamic instability.

Materials and Methods

Materials

All chemicals and materials were purchased from Sigma (St. Louis, MO) unless otherwise noted. Ultima Gold™ scintillation fluid was from PerkinElmer Life and Analytical Sciences (Waltham, MA). The HPLC 10 μ m C-18 column (0.46 $\times$ 25 cm, Vydac) was obtained from the Nest Group. Maytansine was prepared as described previously (17,31) and stored as aliquots of 1 mM stock solutions in DMSO at -70°C . DM1 and tritium-labeled DM1 were prepared from ansamitocin P-3 and [^3H]ansamitocin P-3, respectively (26). S-[^3H]methyl-DM1 was prepared at American Radiochemicals (ARC) by reacting DM1 with [^3H]methyl iodide. Stock solutions were diluted in DMSO to 1 $\mu\text{mol/L}$ and further diluted in cell culture medium or buffer to the desired concentration, with no more than 1:10 dilution at each step. Antibody-DM1 and antibody-[^3H]DM1 conjugates were prepared as described elsewhere (32). The chimeric anti-EpCAM monoclonal antibody, B38.1 and the non-targeting anti-CD56 antibody were produced at ImmunoGen. Conjugates are described by including the abbreviation for the linkers used in conjugation. The ratio of DM1 molecules linked per antibody molecule was determined as previously described (32) and ranged from 3.5–4. AMC concentrations are expressed as the concentration of antibody rather than of the conjugated maytansinoid.

Cell Culture

MCF7 human breast carcinoma cells stably expressing EGFP- α -tubulin (33) were used for all experiments and are referred to as MCF7 cells. The EGFP- α -tubulin-expressing cells were morphologically indistinguishable from unmodified MCF7 (acquired from ATCC) but the doubling time was increased by 20%. They were free of mycoplasma as determined by Hoechst 33342 stain (Life Technologies, Carlsbad, CA, USA) and MycoAlert mycoplasma detection kit (Lonza, Rockland, ME, USA). The expression level of EpCAM was identical on both unmodified MCF7 and EGFP- α -tubulin-expressing MCF7 cells (as verified by binding of muB38.1 antibody)

MCF7 cells were cultured as adherent cells in high glucose (4 g/l) and 25 mmol/L HEPES-fortified DMEM supplemented with 1 $\times$ nonessential amino acids and 10% fetal bovine serum (Hyclone, Logan, UT), and 0.5 mg/mL G418 (Biowhittaker, Rockland, ME) at 37°C in 5.8 % CO_2 . Cells were transferred into medium lacking G418 72 h prior to experiments.

Cell Proliferation

Proliferation was measured by a modified sulforhodamine B (SRB) assay (34). MCF7 cells were seeded at 2×10^4 cells per well in 96-well plates and incubated for 24 h to allow cell attachment and recovery. Medium with or without maytansinoid was then added for a 72 h incubation. Cells were fixed, stained and the optical density (OD) of each well was determined (490 nm, Victor³V Wallac 1420 Spectrophotometer, PerkinElmer, USA). Percentage inhibition of cell proliferation = $100 - [100(\text{OD sample at 72 h} - \text{OD control at 0 h}) / (\text{OD control at 72 h} - \text{OD control at 0 h})]$. The 50% proliferation inhibitory concentrations (antiproliferative IC_{50}) were calculated by fitting the concentration/response data with a sigmoid function using IGOR Pro 6.0 software (WaveMetrics, Lake Oswego, OR). Triplicates of each condition were tested in each experiment. Results are mean and SE of at least three independent experiments.

Cell Cycle and Mitotic Index

MCF7 cells were seeded at 6×10^4 cells per 2 ml into 6-well plates. After a 24 h recovery period, FBS was reduced to 2% for another 24 h (to duplicate the conditions used for imaging dynamic microtubules), then cells were incubated 24 h in culture medium with 10% FBS +/-

maytansinoid. Floating and adherent cells were collected, combined, concentrated by centrifugation, fixed, permeabilized with ice-cold 70% ethanol, washed with PBS, and stained with a Guava Cell Cycle Reagent (Guava Technologies, Hayward, CA) according to the manufacturer's protocol. DNA content of ≥ 3000 cells was measured by flow cytometry on Guava EasyCyte for each condition. Cell cycle distribution was analyzed by ModFit software (Verity Software House, Topsham, ME). Results are mean and SE of at least three independent experiments.

MCF7 cells were grown attached to coverslips pre-treated with poly-L-lysine (400 $\mu\text{g/ml}$) or in 6-well tissue culture plates and incubated with compound identically as for cell cycle experiments. Cells (either on coverslips or detached from 6-well plates by trypsinization) were fixed with 3.7 % formaldehyde, stained with Alexa Fluor 488-conjugated anti-phosphohistone H3 antibody (Cell Signaling Technology, Danvers, MA) and imaged by immunofluorescence microscopy as described below. The proportion of cells that were positive for phosphorylated H3 histone (a mitotic marker) was measured by flow cytometry on Guava EasyCyte (Guava Technologies, Hayward, CA) or by microscopy on the Nikon Eclipse E800 (Nikon, Tokyo, Japan) microscope. The half-maximal mitotic arrest concentrations (IC_{50}) were calculated as described above.

Immunofluorescence Microscopy

Cells were seeded on coverslips as above and incubated with maytansinoid for 24 h, fixed with 3.7 % formaldehyde, and microtubules were stained with mouse monoclonal α -tubulin antibody (DM1A, Sigma-Aldrich, USA) and FITC-conjugated goat anti-mouse antibody (Cappel MP Biochemicals, Solon, OH). Centrosomes were stained with rabbit polyclonal anti-pericentrin antibody (AB4448, Abcam, Cambridge, MA) and rhodamine-conjugated goat anti-rabbit antibody (Cappel MP Biochemicals). Actin filaments were stained with rhodamine-conjugated phalloidin (Invitrogen, Carlsbad, CA). Cells were mounted with 4',6-diamidino-2-phenylindole (DAPI)-containing Prolong Gold (Invitrogen). Microscopy was performed on a spinning disc confocal microscope Olympus IX81 DSU (Olympus, Tokyo, Japan). Images were taken by ImagEM camera (Hamamatsu, Shizuoka, Japan) under control of SlideBook software (Olympus, Tokyo, Japan).

Uptake of S-[^3H]methyl-DM1 by MCF-7 cells

To measure uptake of S-methyl DM1, MCF7 cells (2×10^5 cells/ml) were incubated with 780 pM S-[^3H]-methyl-DM1 (specific activity ~ 500 mCi/mmol), 37°C , 7 h. At each 1 h time point, 1 ml of sample was harvested, cells were separated from the supernatant by centrifugation, and the supernatant was transferred to a 1 ml-Eppendorf tube. Each cell pellet was washed with 10 ml culture media, cells were pelleted by centrifugation, and lysed with 400 μl of lysis buffer (50 mmol/L Tris, pH 8.0, 200 mmol/L NaCl, 15 mmol/L EDTA, 1% v/v Triton-X 100). Radioactivity in lysed cell pellets and supernatants were counted using a Packard Tri-Carb 2900 TR liquid scintillation analyzer (Shelton, CT).

Extraction of [^3H]maytansinoid metabolites following exposure of MCF-7/GFP cells to B38.1-[^3H]DM1 conjugates *in vitro*

Cultures of MCF-7/GFP cells (9×10^6) were exposed to 10nmol/L Ab-[^3H]DM1 conjugates and incubated at 37°C for 5 h, 9 h, or 24 h. The cells were harvested with trypsin, washed with PBS and resuspended in 0.3 mL TBS. The cells treated with the disulfide-linked B38-SPP-[^3H]DM1 were additionally treated with 5 mmol/L N-ethyl maleimide at room temperature for 30 min to alkylate thiol groups. The cell suspensions were assayed for maytansinoid metabolites by HPLC and liquid scintillation counting following acetone extraction as previously described (25).

Live Cell Imaging and Analysis of Microtubule Dynamic Instability

Analysis of microtubule dynamic instability was performed as described previously (33,35) with minor modifications. MCF7 cells were seeded (6×10^4 cells/2 ml) on coverslips coated with poly-L-lysine, laminin and fibronectin in 6-well plates. Cells were incubated for 24 h in culture medium with 10% FBS and then for 24 h in culture medium with 2% FBS to induce flattening after which the maytansinoid was added at the desired concentration. To control for potential rapid loss of drug from cells upon transfer to the imaging medium (cell culture medium lacking sodium bicarbonate and phenol red, but buffered with 25 mmol/L HEPES and supplemented with 10% FBS), a parallel cell-containing well with the same maytansinoid concentration was prepared for each cell sample, with imaging medium replacing the regular culturing medium; this cell-containing coverslip was discarded and the conditioned imaging medium was supplemented with 10 mmol/L DL-lactate and Oxyrase (1:50 final dilution), Oxyrase, Inc. (Mansfield, OH)) and then added to the cell sample to be imaged. Time-lapse images, between 30 and 38 frames at 4-sec intervals, were taken over 1.5 h ($37 \pm 1^\circ\text{C}$) with a $100 \times$ Nikon Plan Apo objective on a Nikon Eclipse E800 microscope (Nikon, Tokyo, Japan) with a CoolSNAP HQ2 camera (Roper Scientific GmbH, Ottobrunn, Germany) under control of MetaMorph software (Molecular Devices, Sunnyvale, CA). For each condition, the plus ends of 18 to 60 dynamic microtubules at the flat lamellar edges of interphase cells were tracked in MetaMorph software for ≥ 60 sec and the distances between an arbitrary microtubule origin point and the plus end were recorded as the microtubule lengths. To analyze dynamic instability, the lengths of individual microtubules were graphed vs. elapsed time as life history plots. Microtubule dynamics were analyzed in IGOR Pro 6.0 software using criteria described in (33,36). Briefly, changes of $\geq 0.5 \mu\text{m}$ were considered growth or shortening events. Changes of $< 0.5 \mu\text{m}$ were called pause (attenuation). The time-based catastrophe frequency is the number of catastrophes (transitions from growth or pause to shortening) divided by the total time spent growing and paused. The rescue frequency is the number of rescues (transitions from shortening to growth or pause) divided by the total time spent shortening. Dynamicity is the total length grown and shortened divided by the life span of the microtubules. Results are the means and SE of at least 3 independent experiments.

Results

Maytansine, S-methyl DM1, and Antibody-Maytansinoid Conjugates Inhibit Proliferation and Arrest Cells at Mitosis

We measured the effects of maytansine, S-methyl DM1 and EpCAM targeting disulfide linked (B38.1-SPP-DM1) and thioether-linked (B38.1-SMCC-DM1) conjugates on proliferation of MCF7 cells over 72 h (Fig. 2A). Both the unconjugated maytansinoids and the conjugated maytansinoids strongly inhibited cell proliferation in concentration-dependent manners. The concentration dependence curves for the inhibition of cell proliferation by the unconjugated compounds (maytansine and S-methyl DM1) were sigmoidal in shape. Minimal inhibition occurred at 400 pmol/L maytansine and at 200 pmol/L S-methyl DM1, respectively, and inhibition was maximal at 6 nmol/L and 3 nmol/L, respectively. For both immunoconjugates minimal inhibition occurred at a concentration of 200 pmol/L, and inhibition increased gradually with increasing concentrations, attaining maxima above 300 nmol/L. S-methyl DM1 ($\text{IC}_{50} = 330 \text{ pmol/L}$) was slightly more potent than maytansine ($\text{IC}_{50} = 710 \text{ pmol/L}$). Both AMCs had similar IC_{50} 's (5.2 nmol/L for uncleavable B38.1-SMCC-DM1 and 11 nmol/L for cleavable B38.1-SPP-DM1). Thus their potencies were between one and two orders of magnitude weaker than the unconjugated maytansinoids. Other studies have reported that the free and conjugated maytansinoids had similar IC_{50} values (32,37). In the previous studies the target antigens were expressed at much higher levels on the cells than the levels for the EpCAM antigen on the MCF-7 cells in the current study.

We determined the concentration dependence for G₂/M arrest at 24 h of incubation (Fig. 2B) by flow cytometry of cells fixed and stained with propidium iodide (Materials and Methods). All four agents induced maxima of 80% accumulation of cells in G₂/M as compared with only 30% in controls (with no drug). The concentration-dependence curves for G₂/M arrest paralleled the curves for inhibition of proliferation. Minimal G₂/M arrest with both maytansine and *S*-methyl DM1 occurred at 200 pmol/L and arrest was maximal at 1 nmol/L, with half-maximal arrest occurring at 310 pmol/L and 340 pmol/L, respectively. Minimal inhibition of G₂/M arrest with both conjugates occurred at 500 pmol/L, reaching maxima at ≥ 100 nmol/L with IC₅₀'s of 7 nmol/L for B38.1-SMCC-DM1 and 10 nmol/L for B38.1-SPP-DM1. Arrest with *S*-methyl DM1 occurred specifically in mitosis as determined by immunostaining with antibodies against phosphorylated histone H3, a marker for mitotic cells. As shown in Fig. 2C, half-maximal mitotic arrest with *S*-methyl DM1 (IC₅₀, 0.4 nmol/L) occurred at the same concentration as G₂/M arrest.

The antibody specificity of the conjugate-induced cell cycle arrest was examined in two ways. Incubation of the cells with 11 nmol/L B38.1-SPP-DM1 in the presence of a 90-fold excess of unconjugated B38.1 antibody (1 μ mol/L) induced no cell cycle arrest or inhibition of proliferation (data not shown). In addition, incubation of cells with Ab-SPP-DM1 and Ab-SMCC-DM1 conjugates that do not bind to any antigens on the MCF-7/GFP cells also induced no cell cycle arrest or inhibition of proliferation. These observations indicate that the activity of the B38-DM1 conjugates is antigen-specific.

Effects of *S*-methyl DM1 on Microtubule Organization

To assess the effects of *S*-methyl DM1 on the microtubule network, cells were fixed and stained for microtubules, actin and chromatin and examined by immunofluorescence microscopy (Materials and Methods). In control cells in interphase, microtubules formed a fine filamentous network throughout the cell and actin formed a filamentous network at the cell periphery (Fig. 3Aa). After 24 h incubation with 340 pmol/L *S*-methyl DM1 (the IC₅₀ for mitotic arrest) some interphase cells were slightly rounded, but the microtubules and actin fibers in these cells (Fig. 3Ab) were indistinguishable from microtubules in control interphase cells.

At an *S*-methyl DM1 concentration of 680 pmol/L ($2 \times$ IC₅₀) the microtubules in interphase cells were shorter, fewer in number, and had a patchy distribution; small aggregates of tubulin were also apparent (Fig 3Ac, arrowheads and arrows, respectively). The actin fiber network was unchanged. At 1.4 nmol/L *S*-methyl DM1 ($4 \times$ IC₅₀) no microtubules remained, most cells were rounded, and the actin occupied a narrow region at the cell periphery (Fig. 3Ad).

Mitotic spindle organization was examined in cells that were fixed and stained for microtubules, centrosomes and chromatin. Control mitotic cells had well-separated centrosomes, and well-formed bipolar spindles with only a few astral microtubules at the poles (Fig. 3B, e). All chromosomes in control metaphase spindles had congressed into a compact central metaphase plate.

The maytansinoids induced structural and functional spindle microtubule abnormalities at concentrations that induced little or no detectable change in the microtubule network of interphase cells. *S*-methyl DM1 at $1 \times$ IC₅₀ (340 pmol/L) induced striking abnormalities in mitotic cells (Fig. 3Bf–j). The majority had abnormal spindles classified as Type I (Fig. 3Bf) or Type II bipolar spindles, using the classification of Jordan et al, 1991 (38) and Ngan et al, 2001 (39), with more and longer astral microtubules than in spindles in control cells, some uncongressed chromosomes, and reduced interpolar distances (data not shown) (Fig. 3Bg,h). A few cells had spindles that were normal and bipolar with compact metaphase plates of congressed chromosomes whereas a few mitotically-arrested cells had Type III abnormal ball-shaped spindles that were often monoastral with little, if any, separation of the centrosomes

(Fig. 3Bi,j). Chromosomes and star-like aggregates of thick microtubules surrounded the centrosomes.

S-methyl DM1 at $2\text{--}4 \times$ mitotic IC_{50} (680 pmol/L - 1.4 nmol/L) induced predominantly Type III spindles and increasing numbers of Type IV abnormal spindles. In Type IV abnormal spindles (Fig. 3Bk,l) only a few short thick microtubules surrounded unseparated or poorly separated centrosomes. There were frequent small tubulin aggregates and bundles of short microtubules that were not connected to the centrosomes. Interestingly, in contrast to other microtubule-interacting compounds, no multipolar spindles occurred at any *S*-methyl DM1 concentration. Similar concentration-dependent changes in spindle organization occurred upon treatment with free maytansine and the B38.1-DM1 conjugates (data not shown). Interestingly, the variety of abnormal spindles for any given concentration and the range of effects on interphase microtubules were greater with the immunoconjugates than with unconjugated maytansinoids suggesting that the response varied significantly from cell to cell due, perhaps due to variable uptake of the immunoconjugates resulting from variations in antigen density.

Cellular Uptake of *S*-[^3H]methyl-DM1 and and Metabolism of B38.1-SMCC-[^3H]DM1 and B38.1-SPP-[^3H]DM1

We examined the time course for uptake of *S*-[^3H]methyl-DM1 into MCF7 cells. As shown in Fig. 4A, at a concentration of 780 pmol/L, *S*-[^3H]methyl-DM1 was taken up relatively rapidly attaining an intracellular concentration of ~ 100 nmol/L at 1 h and a concentration of 400 nmol/L at 5 h.

To determine the time course for uptake and metabolism of the B38.1-DM1 conjugates, MCF7 cells were exposed to 10 nmol/L B38.1-SPP-[^3H]DM1 or 10 nmol/L B38.1-SMCC-[^3H]DM1 for 5 h, 9 h or 24 h. The cells were then analyzed for [^3H]maytansinoid metabolites by HPLC and liquid scintillation counting following acetone extraction (Fig. 4C). The observed metabolites had retention times identical to the target cell metabolites identified by LCMS for the anti-CanAg conjugates, huC242-SPP-DM1 and huC242-SMCC-DM1 (26). At 5 and 10 h, lysine-linker-maytansinoid adducts (DM1-SPP-lysine and DM1-SMCC-lysine) were the primary accumulated metabolites of the two conjugates. Even after a prolonged (24 h) incubation of the cells with B38.1-SMCC-[^3H]DM1 (Fig. 4C, left column), DM1-SMCC-lysine was the major metabolite. In contrast, the lysine-linker-maytansinoid adduct derived from the cleavable EpCAM-SPP-[^3H]DM1 (Fig. 4C, right column) was accompanied at 10 h by unconjugated DM1 that resulted from the intracellular reduction of the disulfide bond connecting the cross-linker and DM1. At 24 h, similar levels of the cellular metabolites for the two conjugates formed as indicated by the areas under the peaks. This suggests that the rates for the initial steps through the lysosomal degradation shown in Fig 4B are similar for the two conjugates. As shown in the bottom two panels of Fig. 4C, a 100-fold excess of unconjugated EpCAM antibody (1 $\mu\text{mol/L}$) significantly blocked cellular uptake and catabolism of the conjugates.

Maytansine and *S*-methyl DM1 Suppress Dynamic Instability of Microtubules in Cells at Concentrations that Arrest Mitosis

We examined the effects of the free maytansinoids, *S*-methyl DM1 and maytansine, at their mitotic IC_{50} 's, on dynamic instability of individual microtubules in MCF7 cells at 5 h-incubation, a time when the intracellular drug concentrations had attained equilibrium (Fig. 3A). Fig. 5A shows representative frames from a time-lapse series of control cells and from cells incubated with 340 pmol/L *S*-methyl DM1, showing the changes in length of individual microtubules over time. The length changes were measured (Materials and Methods), and "life history plots" of the changes of the individual microtubules over time (Fig. 5B) were used to determine the parameters of dynamic instability (Table 1A). In control cells most of the

microtubules were dynamic, undergoing frequent transitions between relatively slow growth and rapid shortening. Plus ends of microtubules in control cells shortened at a rate of $20.0 \pm 2.3 \mu\text{m}/\text{min}$ and grew at a rate of $12.9 \pm 1.0 \mu\text{m}/\text{min}$ (Table 1A). They underwent catastrophes at a frequency of $2.3 \pm 0.3/\text{microtubule}/\text{min}$ and transitioned to growth or attenuation from shortening (called rescue) at a frequency of $6.6 \pm 0.5/\text{microtubule}/\text{min}$. Their overall dynamicity (the total rate of exchange of tubulin with the microtubule end expressed as microtubule length per time) was $12.0 \pm 0.6 \mu\text{m}/\text{min}$.

In contrast, as shown in Table 1A, nearly half of the microtubules in cells incubated with either maytansine (310 pmol/L) or *S*-methyl DM1 (340 pmol/L) (the mitotic IC_{50} 's of the two drugs) were not dynamic; they did not grow or shorten detectably during the observation time. The dynamic instability of microtubules that retained dynamic behavior was significantly suppressed; they grew and shortened more slowly than microtubules in control cells. Maytansine had a somewhat stronger suppressive effect than *S*-methyl DM1 (Table 1A). The shortening rates were suppressed by maytansine and *S*-methyl DM1 by 45% and 22%, respectively, and the growth rates were suppressed by 37% and 28%, respectively. Maytansine and *S*-methyl DM1 suppressed the catastrophe frequency, by 61% and 36%, respectively, and enhanced the rescue frequency by 19% and 68%, respectively. Dynamicity was suppressed 65% by maytansine and 58% by *S*-methyl DM1. The magnitude of suppression increased when the concentration of maytansine or *S*-methyl DM1 was increased from $1 \times \text{IC}_{50}$ to $2 \times \text{IC}_{50}$ (data not shown).

Antibody-Maytansinoid (B38.1-DM1) Conjugates Suppressed Dynamic Instability in Parallel with Intracellular Metabolite Formation

To determine whether the conjugate metabolites play a significant role in the antiproliferative and antimitotic mechanisms of the antibody-maytansinoid conjugates, we examined the relationship between metabolite formation and suppression of dynamic instability in the cells. Cells were incubated with 10 nmol/L B38.1-SMCC-DM1 or B38.1-SPP-DM1 for 5, 10 and 24 h. This concentration approximates the antimitotic IC_{50} 's of the immunoconjugates (which were 7 nmol/L for the uncleavable B38.1-SMCC-DM1 and 10 nmol/L for the cleavable B38.1-SPP-DM1 (Fig. 2B) and is the same concentration used in the uptake and metabolism study (Fig. 4C). Incubation with either immunoconjugate for 5 h moderately suppressed microtubule dynamic instability; the suppressive effects increased at 10 h and 24 h (Table I B and C). Similar to *S*-methyl DM1 and maytansine, incubation with B38.1-SMCC-DM1 and B38.1-SPP-DM1 for 5 h reduced growth rates by 10% and 17%, respectively, shortening rates by 31% and 28%, respectively, and catastrophe frequencies by 48% and 25%, respectively. As shown in Fig. 5C and Table 1B, the suppressive effects on dynamic instability were proportional to the increase in intracellular concentration of the metabolites, attaining 45% and 50% suppression of growth rates, 45% and 61% suppression of shortening rates, and 50% and 75% suppression of the catastrophe frequency for the two immunoconjugates, respectively, at 24 incubation. The overall dynamicity at 5 h was suppressed 37% and 46% by B38.1-SMCC-DM1 and B38.1-SPP-DM1, respectively, and increased to 75% and 83%, respectively, at 24 h. The time dependence for inhibition of dynamicity as compared with the appearance of the metabolites is shown in Fig. 5. Thus, the cleavable and uncleavable B38.1-DM1 conjugates both disrupt microtubule dynamic instability in concert with the cellular accumulation of their metabolites. As a control, we added a 100-fold excess of unconjugated B38.1 antibody (1 $\mu\text{mol}/\text{L}$) simultaneously with the conjugates. This completely prevented suppression of microtubule dynamic instability (data not shown), indicating that antibody-mediated uptake of the B38-DM1 conjugates is required to suppress dynamic instability.

Discussion

We found that maytansine, *S*-methyl DM1, and the anti-EpCAM antibody-maytansinoid conjugates, B38.1-SPP-DM1 and B38.1-SMCC-DM1 all inhibited proliferation of MCF7 cells at subnanomolar or nanomolar concentrations in concert with mitotic arrest and suppression of microtubule dynamic instability. Internalization and metabolism of the conjugates led to continued potent suppression of dynamic instability indicating that the metabolites and the free unconjugated maytansinoids exert their potent antimitotic effects via a common mechanism involving suppression of microtubule dynamic instability.

Proliferation

We found that maytansine, *S*-methyl DM1, and the anti-EpCAM conjugates, B38.1-SPP-DM1 and B38.1-SMCC-DM1 all inhibited proliferation of MCF7 cells with IC₅₀ values of 710 pmol/L for maytansine, 330 pmol/L for *S*-methyl DM1, 5.2 nmol/L for B38.1-SPP-DM1 and 11 nmol/L for B38.1-SMCC-DM1. The differences in potency between the conjugates and the free maytansinoids may be attributed to the relatively low expression of the EpCAM antigen on the MCF7 cells. Indeed, the B38.1-SMCC-DM1 conjugate was shown to be much more cytotoxic towards other carcinoma cells than is reported here with MCF7 cells, presumably due to the higher levels of the EpCAM antigen on the other cells (40). Also, in a related study, the cytotoxic potencies of CanAg-targeting antibody maytansinoid conjugates towards cell lines with high levels of the target antigen were found to be similar to the potencies of the free maytansine and *S*-methyl DM1 (26,32). We found that the concentration response curves for the free maytansinoids were steep and S-shaped, whereas the response curves for both conjugates were more linear and increased relatively slowly. This difference in response most likely results from the different mechanisms of cellular uptake for free and conjugated maytansinoids and from the relatively low expression level of the EpCAM antigen on the MCF-7 cells as compared with expression of HER2-in the previous studies with the trastuzumab-DM1 conjugate (32,37).

Inhibition of Proliferation Occurred in Concert with Mitotic Arrest

G₂/M arrest was induced half-maximally for each compound at a concentration that was similar to the concentration that inhibited proliferation by 50% (half maximal G₂/M arrest at 310 pmol/L maytansine, 340 pmol/L *S*-methyl DM1, 6.8 nmol/L B38.1-SMCC-DM1, and 10.5 nmol/L B38.1-SPP-DM1). Staining of cells by DAPI and phosphohistone-H3 antibody indicated that mitotic arrest occurred predominantly in prometaphase/metaphase of mitosis and that the drugs induced significant drug-concentration dependent abnormalities in the arrested spindles. Thus inhibition of proliferation occurred by mitotic arrest. Interphase microtubule arrays were normal except at high drug concentrations (2–4 × IC₅₀) at which microtubules were depolymerized, and some tubulin accumulations or aggregates formed.

The maytansinoid-induced spindle abnormalities were strikingly similar to those induced by other microtubule-interacting compounds including vinca alkaloids, 2-methoxyestradiol, taxanes, podophyllotoxin, nocodazole, sulfuraphane, and eribulin (35,38,39,41). The abnormalities included a concentration-dependent increase in the number of uncongressed chromosomes, an increase in the number of astral microtubules, and a shortened pole-to-pole distance. At very high concentrations spindles were monopolar with a spherical central accumulation of condensed chromosomes and star-shaped aggregates of short, thick microtubules. The failure of congression is likely due to the inability of both kinetochores of sister chromosomes to secure proper attachments to microtubules from opposite poles due to the suppressed dynamic instability of spindle microtubules. The shortened pole-to-pole distance is also likely due to suppression of microtubule dynamics and/or to some microtubule

depolymerization. Interestingly, we observed no multipolar spindles, suggesting that centrosomal duplication or integrity was unaffected.

Antibody-Maytansinoid Conjugates (B38.1-SPP-DM1 and B38.1-SMCC-DM1) are Internalized in an Antigen-Specific Manner and Metabolized

Since we found that an excess of unconjugated antibody prevented internalization of both the cleavable and uncleavable B38-DM1 conjugates, it is clear that they were internalized by cells in an antigen-specific manner;. The lysine adduct produced by metabolism of the uncleavable B38-SMCC-DM1 (Lys-SMCC-DM1) was detected in the cells after 5 h of incubation, and the quantity continued to increase after 10 h and 24 h of incubation. While the analogous lysine-SPP-DM1 metabolite of the B38-SPP-DM1 conjugate was observed in cells at 5 h and increased in quantity at 10 h, it underwent an additional reduction to yield DM1 itself at 24 h. The appearance of the Lys-SPP-DM1 metabolite prior to the DM1 indicated that lysosomal degradation of the antibody component preceded reduction of the disulfide bond in the chemical linker to produce DM1. These findings are in concert with previous studies on metabolism of cleavable and uncleavable antibody-maytansinoid conjugates (25).

Maytansinoids Suppress Dynamic Instability Similarly in Cells and with Purified Microtubules In Vitro

The characteristics of maytansinoid-induced suppression of dynamic instability in cells are similar in most respects qualitatively and quantitatively to results on the suppressive effects of maytansine and *S*-methyl DM1 on dynamic instability of purified bovine brain microtubules reported in the accompanying manuscript (30). For example, 340 pmol/L *S*-methyl DM1 added to MCF7 cells suppressed microtubule growth rates 22%, compared with 24% suppression by 100 nmol/L *S*-methyl DM1 with purified microtubules. Similarly, shortening rates were suppressed 28% and 67%, respectively; the catastrophe frequency was suppressed by 36% and 90%, respectively; and overall dynamicity was suppressed by 58% and 84%, respectively.

Comparing the intracellular concentration of *S*-methyl DM1 with the concentration that was added to the medium indicated that the intracellular concentration increased about 500-fold. (Addition of 780 pmol/L *S*-methyl DM1 to the cells resulted in an intracellular concentration of 400 nmol/L, Fig. 4A.) A similar cellular uptake phenomenon is frequently observed with other microtubule-targeted drugs (42,43). From these data we estimate that the addition of 340 pmol/L *S*-methyl DM1 to the cells would have resulted in an intracellular concentration of approximately 80 nmol/L *S*-methyl DM1, similar to the concentration of 100 nmol/L that was used *in vitro* with purified microtubules. Thus the effective concentrations in cells and *in vitro* with purified microtubules are similar.

The only significant difference between the dynamics results in cells and *in vitro* was that the rescue frequency was affected in opposite ways in the two environments. It was reduced by 44% by 100 nmol/L *S*-methyl DM1 with purified microtubules whereas it was increased 68% by 340 pmol/L *S*-methyl DM1 in cells. A possible explanation for this difference is that microtubule tips that are not capped by GTP-tubulin but instead have exposed GDP-tubulin at their tips are thought to have an unstable conformation that can undergo rapid microtubule depolymerization. Rescue of such a rapid shortening or depolymerization event may occur at microtubule regions where tubulin with bound GTP or with a GTP-like conformation exist in the body of the microtubule (44). It is conceivable that in the complex milieu of the cell, maytansine or *S*-methyl DM1 interacts with some of the many proteins that associate with microtubules (microtubule-associated proteins, protein motors, etc.) and thereby prevents some regions of the microtubule from completing GTP hydrolysis or from attaining the unstable GDP-associated conformation thus increasing the rescue frequency, whereas *in vitro* with

purified microtubules and no microtubule-associated proteins, such stabilized regions may not exist.

In all respects except for the opposite effects on rescue frequency the *in vitro* results are similar to the results reported for cells (Table 1) indicating that the maytansinoid mechanisms in the complex milieu of the cell are similar to those *in vitro*. Thus, both in cells and *in vitro*, at low concentrations (those that induce mitotic arrest), it appears that maytansinoids stabilize microtubule dynamics by suppressing microtubule growth and shortening and catastrophe by binding with high affinity to a few sites at microtubule ends (30). At higher concentrations, the maytansinoids depolymerize microtubules both *in vitro* and in cells.

Metabolites Suppressed Dynamic Instability Similarly to the Unconjugated Compound, in Concert with their Cellular Accumulation

Like the free maytansinoids, the cleavable and uncleavable B38.1-DM1 conjugates and their metabolites inhibited cell proliferation and arrested cells in mitosis by suppressing microtubule dynamic instability. Dynamic instability was significantly inhibited by the low levels of metabolites produced at 5 h of incubation and inhibition increased significantly after 10 h and 24 h incubation (Table 1 and Fig 5). At the concentrations that induced half-maximal G2/M arrest, the conjugates suppressed or enhanced the same microtubule dynamics parameters to similar degrees and in similar directions as free *S*-methyl DM1 and maytansine. Both growth and shortening rates, the catastrophe frequency, and dynamicity were suppressed by all four maytansinoids, and the rescue frequency was enhanced. As shown in Fig. 5CD, the time dependence for increased effects on microtubule dynamicity paralleled the increase in intracellular metabolite concentration arising from metabolism of B38.1-SMCC-DM1. For the cleavable B38.1-SPP-DM1, the time dependence for the sum of the concentrations of the two metabolites approximately paralleled the time dependence for increase in suppression of microtubule dynamicity. Thus, the results indicate that the metabolites and the free unconjugated maytansinoids have similar mechanisms of action, exerting their antiproliferative effects by inhibiting mitosis through suppression of microtubule dynamic instability.

Acknowledgments

Grant Support: Supported by grants from USPHS CA 57291 and NS13560

Abbreviations

AMC	antibody-, maytansinoid conjugate
B38.1	anti-EpCAM monoclonal antibody
DMSO	dimethylsulfoxide
DMEM	Dulbecco's modified Eagle's medium
EpCAM	Epithelial cell adhesion molecule
FBS	fetal bovine serum
FITC	fluorescein isothiocyanate
DAPI	4',6-diamidino-2-phenylindole
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
OD	optical density
HPLC	high pressure liquid chromatography
SMCC	succinimidyl-4-(<i>N</i> -maleimidomethyl)-cyclohexane-1-carboxylate

S P P *N*-succinimidyl-4-(2-pyridyldithio)-pentanoate

References

1. Kupchan SM, Komoda Y, Branfman AR, et al. The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. *The Journal of organic chemistry* 1977 Jul 8;42(14):2349–57. [PubMed: 874612]
2. Kupchan SM, Komoda Y, Court WA, et al. Maytansine, a novel antileukemic ansa macrolide from *Maytenus ovatus*. *Journal of the American Chemical Society* 1972 Feb 23;94(4):1354–6. [PubMed: 5062169]
3. Kupchan SM, Sneden AT, Branfman AR, et al. Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. *Journal of medicinal chemistry* 1978 Jan;21(1):31–7. [PubMed: 563462]
4. Sieber SM, Wolpert MK, Adamson RH, Cysyk RL, Bono VH, Johns DG. Experimental studies with maytansine--a new antitumor agent. *Bibliotheca haematologica* 1975 Oct;(43):495–500. [PubMed: 1067087]
5. Wolpert-DeFilippes MK, Bono VH Jr, Dion RL, Johns DG. Initial studies on maytansine-induced metaphase arrest in L1210 murine leukemia cells. *Biochemical pharmacology* 1975 Sep 15;24(18):1735–8. [PubMed: 1238093]
6. Bhattacharyya B, Wolff J. Maytansine binding to the vinblastine sites of tubulin. *FEBS letters* 1977 Mar 15;75(1):159–62. [PubMed: 852577]
7. Mandelbaum-Shavit F, Wolpert-DeFilippes MK, Johns DG. Binding of maytansine to rat brain tubulin. *Biochemical and biophysical research communications* 1976 Sep 7;72(1):47–54. [PubMed: 985482]
8. Sieber SM, Mead JA, Adamson RH. Pharmacology of antitumor agents from higher plants. *Cancer treatment reports* 1976 Aug;60(8):1127–39. [PubMed: 136296]
9. Remillard S, Rebhun LI, Howie GA, Kupchan SM. Antimitotic activity of the potent tumor inhibitor maytansine. *Science (New York, NY)* 1975 Sep 19;189(4207):1002–5.
10. Huang AB, Lin CM, Hamel E. Maytansine inhibits nucleotide binding at the exchangeable site of tubulin. *Biochemical and biophysical research communications* 1985 May 16;128(3):1239–46. [PubMed: 4004859]
11. Issell BF, Crooke ST. Maytansine. *Cancer treatment reviews* 1978 Dec;5(4):199–207. [PubMed: 367597]
12. Chari RV. Targeted cancertherapy: conferring specificity to cytotoxic drugs. *Accounts of chemical research* 2008 Jan;41(1):98–107. [PubMed: 17705444]
13. Ricart AD, Tolcher AW. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. *Nature clinical practice* 2007 Apr;4(4):245–55.
14. Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. *Cancer letters* 2007 Oct 8;255(2):232–40. [PubMed: 17553616]
15. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. *Nature biotechnology* 2005 Sep;23(9):1137–46.
16. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. *Current opinion in pharmacology* 2005 Oct;5(5):543–9. [PubMed: 16087399]
17. Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. *Cancer research* 1992 Jan 1;52(1):127–31. [PubMed: 1727373]
18. Liu C, Tadayoni BM, Bourret LA, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. *Proceedings of the National Academy of Sciences of the United States of America* 1996 Aug 6;93(16):8618–23. [PubMed: 8710920]
19. Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. *Cancer research* 2006 Mar 15;66(6):3214–21. [PubMed: 16540673]

20. Tolcher AW, Ochoa L, Hammond LA, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. *J Clin Oncol* 2003 Jan 15;21(2):211–22. [PubMed: 12525512]
21. Tijink BM, Buter J, de Bree R, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. *Clin Cancer Res* 2006 Oct 15;12(20 Pt 1):6064–72. [PubMed: 17062682]
22. Helft PR, Schilsky RL, Hoke FJ, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. *Clin Cancer Res* 2004 Jul 1;10(13):4363–8. [PubMed: 15240523]
23. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. *J Clin Oncol* 2010 Jun 1;28(16):2698–704. [PubMed: 20421541]
24. Smith SV. Technology evaluation: huN901-DM1, ImmunoGen. Current opinion in molecular therapeutics 2005 Aug;7(4):394–401. [PubMed: 16121706]
25. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. *Cancer research* 2006 Apr 15;66(8):4426–33. [PubMed: 16618769]
26. Erickson HK, Widdison WC, Mayo MF, et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. *Bioconjugate chemistry* 2010 Jan;21(1):84–92. [PubMed: 19891424]
27. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. *Nature reviews* 2004 Apr;4(4):253–65.
28. Jordan MA, Kamath K. How do microtubule-targeted drugs work? An overview. *Current cancer drug targets* 2007 Dec;7(8):730–42. [PubMed: 18220533]
29. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. *Current medicinal chemistry* 2002 Jan;2(1):1–17. [PubMed: 12678749]
30. Lopus M, Oroudjev E, Wilson L, et al. Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules. *Molecular cancer therapeutics*. 2010 (accepted).
31. Xie H, Audette C, Hoffee M, Lambert JM, Blattler WA. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. *The Journal of pharmacology and experimental therapeutics* 2004 Mar;308(3):1073–82. [PubMed: 14634038]
32. Widdison WC, Wilhelm SD, Cavanagh EE, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. *Journal of medicinal chemistry* 2006 Jul 13;49(14):4392–408. [PubMed: 16821799]
33. Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. *Cancer research* 2003 Sep 15;63(18):6026–31. [PubMed: 14522931]
34. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. *Journal of the National Cancer Institute* 1990 Jul 4;82(13):1107–12. [PubMed: 2359136]
35. Kamath K, Okouneva T, Larson G, Panda D, Wilson L, Jordan MA. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. *Molecular cancer therapeutics* 2006 Sep;5(9):2225–33. [PubMed: 16985056]
36. Kamath, K.; Oroudjev, E.; Jordan, MA. Determination of Microtubule Dynamic Instability in Living Cells. In: Cassimeris, L., editor. *Methods in Cell Biology*. 2010. in press
37. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. *Cancer research* 2008 Nov 15;68(22):9280–90. [PubMed: 19010901]
38. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. *Cancer research* 1991 Apr 15;51(8):2212–22. [PubMed: 2009540]
39. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. *Molecular pharmacology* 2001 Jul;60(1):225–32. [PubMed: 11408618]

40. Kovtun YV, Audette CA, Mayo MF, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. *Cancer research* 2010 Mar 15;70(6):2528–37. [PubMed: 20197459]
41. Azarenko O, Okouneva T, Singletary KW, Jordan MA, Wilson L. Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane. *Carcinogenesis* 2008 Dec;29(12):2360–8. [PubMed: 18952594]
42. Jordan, MA.; Wilson, L. *Methods in Cell Biology*. Academic Press; 1999. The use and action of drugs in analyzing mitosis; p. 267-95.
43. Jordan, MA.; Wilson, L. The use of drugs to study the role of microtubule assembly dynamics in living cells. In: Vallee, R., editor. *Molecular Motors and the Cytoskeleton, Methods in Enzymology*. Academic Press; 1998. p. 252-76.
44. Dimitrov A, Quesnoit M, Moutel S, Cantaloube I, Pous C, Perez F. Detection of GTP-tubulin conformation in vivo reveals a role for GTP remnants in microtubule rescues. *Science (New York, NY)* 2008 Nov 28;322(5906):1353–6.

Figure 1.
Structures of maytansine, DM1 and *S*-methyl DM1 (For DM1: R=H, For *S*-methyl DM1: R=Me), DM1 immunconjugates, DM1-SMCC-lys metabolite.

Figure 2.

Concentration dependence for (A) inhibition of proliferation, (B) G₂/M arrest and (C) mitotic arrest of MCF7 cells by maytansinoids and their antibody conjugates. Cells were incubated with (○) maytansine, (●) *S*-methyl DM1, (□) B38.1-SPP-DM1 and (■) B38.1-SMCC-DM1. (A) Cells were incubated with compound for 72 h and inhibition of proliferation was measured by SRB (Materials and Methods). Maytansine, *S*-methyl DM1, B38.1-SPP-DM1 and B38.1-SMCC-DM1 inhibited proliferation with IC₅₀ values 710 pmol/L, 330 pmol/L, 11 nmol/L and 5.2 nmol/L, respectively. (B) Cells were incubated with compounds for 24 h and the population of G₂/M cells was determined by flow cytometry (Materials and Methods). Maytansine, *S*-methyl DM1, B38.1-SPP-DM1 and B38.1-SMCC-DM1 induced arrest in G₂/M with IC₅₀ values 310 pmol/L, 340 p mol/L, 10 nmol/L and 6.8 nmol/L, respectively. (C) Cells were incubated with *S*-methyl DM1 for 24 h and the percentage of cells that stained positively for phosphorylated histone H3 was determined by flow cytometry or counted by microscopy (Materials and Methods). *S*-methyl DM1 induced mitotic arrest with an IC₅₀ of 400 nmol/L. Results are means and standard error of at least three experiments.

Figure 3.

Effects of *S*-methyl DM1 on microtubule organization in interphase and mitosis. **(A)** **Interphase:** MCF7 cells were fixed and stained for α -tubulin (green), actin (red) and DNA (blue). Control cells (a) and cells treated for 24 h with 340 pmol/L (mitotic IC₅₀) *S*-methyl DM1 (b) show intact microtubule and actin networks with similar overall morphologies. (c) At 680 pmol/L *S*-methyl DM1 (2 × mitotic IC₅₀), microtubules were significantly shorter (arrowheads), reduced in number, and showed a patchy distribution. Some tubulin aggregates are visible (arrows). At 1.4 nmol/L *S*-methyl DM1 (4 × mitotic IC₅₀) (d) all microtubules were depolymerized and actin formed a narrow band at the cell periphery. Scale bar = 10 μm. **(B)** **Mitosis:** MCF7 cells were incubated for 24 h with medium alone (e) or with 340 pmol/L (1 × mitotic IC₅₀) (f,g,h,i,j) or 680 pmol/L *S*-methyl DM1 (2 × mitotic IC₅₀) (k,l). Cells were fixed and stained for α -tubulin (green), the centrosome-associated protein pericentrin (red) and DNA (blue). In control mitotic cells (e), spindles were normal with well-separated centrosomes and with the chromosomes congressed to a compact metaphase plate. The majority of cells arrested in mitosis by *S*-methyl DM1 displayed some abnormalities in metaphase: uncongressed chromosomes (red arrows), poorly-defined bipolar spindles or monopolar spindles, an increased number of astral microtubules, and poorly-separated centrosomes (white arrows). Based on these morphological abnormalities cells were categorized into Type I, Type II, Type III and Type IV spindles (see Results). Scale bar = 5 μm.

Figure 4.

Comparison of the cellular accumulation of S-[^3H]methyl-DM1 with accumulation of the metabolites of cleavable and uncleavable B38.1-SPP-[^3H]DM1 conjugates. (A) Time course of uptake of 780 pmol/L [^3H]-S-methyl DM1 by MCF7 cells. (B) Radio chromatograms of the [^3H] maytansinoid metabolites of B38.1-SPP-[^3H]DM1 and B38.1-SMCC-[^3H]DM1. MCF-7 cells were exposed to the B38.1-SPP-[^3H]DM1 conjugates for the indicated of the homogenates were assayed for ^3H -maytansinoid metabolites by extraction and HPLC. The effluent from the samples was collected in 1 mL fractions and the radioactivity corresponding to each fraction was determined by LSC. The counts per minute of tritium (CPM) associated with the fractions was plotted vs. the time the fraction was collected. . The lowest two panels show that co-incubation with 1 $\mu\text{mol/L}$ unconjugated EpCAM antibody strongly inhibited the formation of the metabolites. (C) Diagram depicting the cellular uptake and processing of the anti-EpCAM antibody-DM1 conjugates, B38.1-SMCC-DM1 and B38.1-SPP-DM1. Both conjugates are internalized by antigen-mediated endocytosis. The endosomes containing conjugate fuse with lysosomes, and the conjugates undergo proteolysis forming the corresponding lysine-linker-maytansinoids, lysine-SMCC-DM1 and lysine-SPP-DM1. The lysine-SPP-DM1 metabolite of the cleavable conjugate is further reduced to yield free DM1 while the lysine-SMCC-DM1 metabolite of the uncleavable conjugate resists additional processing.

Figure 5.

Dynamic instability of microtubules in MCF7 cells incubated with maytansine, *S*-methyl DM1, B38.1-SMCC-DM1, and B38.1-SPP-DM1. Cells were incubated for 5 h with 310 pmol/L maytansine, 340 pmol/L *S*-methyl DM1, 10.5 nmol/L B38.1-SPP-DM1 and 6.8 nmol/L B38.1-SMCC-DM1 ($1 \times IC_{50}$ concentrations of corresponding compounds) or medium alone. Time-lapse images (**A**) of individual microtubules in the lamellar periphery of cells were recorded by epifluorescence microscopy. Microtubule ends (black triangles) were tracked over time to produce life history plots. (**B**) Life history plots of length of individual microtubules. In all cells treated with maytansinoids the dynamic instability of individual microtubules was visibly suppressed. (**C and D**) Over the 24-h time course of incubation with B38.1-SMCC-DM1 (**C**) and B38.1-SPP-DM1 (**D**) suppression of microtubule dynamics (left axes) increased similarly with the increase in the intracellular concentration of the metabolite of the B38.1-DM1 conjugates as determined by the AUC (area under the curve)(right axes) as shown in Fig. 4C.

Suppression of microtubule dynamic instability in MCF7 cells by maytansine and S-methyl DM1 after 5 h incubation with cell cycle 1×IC₅₀ concentrations

Table 1A

MT Dynamic Instability Parameters	Control	S-methyl DM1 (340 pmol/L)	% change	maytansine (310 pmol/L)	% change
Growth Rate (GR), $\mu\text{m}/\text{min}$	12.9 $\pm$ 1.0	9.9 $\pm$ 1.2**	-22	6.9 $\pm$ 0.5**	-45
Shortening Rate (SR), $\mu\text{m}/\text{min}$	20.0 $\pm$ 2.3	14.3 $\pm$ 1.6 **	-28	12.5 $\pm$ 1.3**	-37
% Time Spent Growing (TG)	51	27	-47	30	-41
% Time Spent Shortening (TS)	26	14	-45	11	-58
% Time Spent Attenuated (TA)	23	59	157	59	158
Catastrophe Frequency (CF), $\#/\text{MT}/\text{min}$	2.5 $\pm$ 0.3	1.6 $\pm$ 0.2 *	-36	1.0 $\pm$ 0.1**	-61
Rescue Frequency (RF), $\#/\text{MT}/\text{min}$	6.6 $\pm$ 0.5	11.0 $\pm$ 0.7**	68	7.8 $\pm$ 0.6	19
Growth Distance (GD), $\#/\text{MT}/\mu\text{m}$	0.36 $\pm$ 0.06	0.77 $\pm$ 0.20	113	0.49 $\pm$ 0.07	35
Shortening Distance (SD), $\#/\text{MT}/\mu\text{m}$	0.35 $\pm$ 0.04	1.11 $\pm$ 0.11**	213	0.83 $\pm$ 0.10**	136
Dynamicity	12.0 $\pm$ 0.6	5.0 $\pm$ 0.6**	-58	4.3 $\pm$ 0.3**	-65
Non-dynamic microtubules	5%	45%		48%	

Table 1B

Time dependence for suppression of microtubule dynamic instability in MCF7 cells by 10 nmol/L EpCAM-SMCC-DM1

MT Dynamic Instability Parameters	Control	5 hours	% change	10 hours	% change	24 hours	% change
Growth Rate (GR), $\mu\text{m}/\text{min}$	12.9 ± 1.0	11.4 ± 1.2	-10	11.7 ± 1.6	-8	$6.95 \pm 0.5^{**}$	-45
Shortening Rate (SR), $\mu\text{m}/\text{min}$	20.0 ± 2.3	$13.6 \pm 1.2^{**}$	-31	$13.7 \pm 2.4^{**}$	-31	$11.0 \pm 1.0^{**}$	-45
% Time Spent Growing (TG)	51	43	-16	39	-24	17	-67
% Time Spent Shortening (TS)	26	15	-41	9	-65	7	-74
% Time Spent Attenuated (TA)	23	42	83	52	130	76	235
Catastrophe Frequency (CF), #/MT/min	2.5 ± 0.3	$1.3 \pm 0.1^{**}$	-48	$1.1 \pm 0.2^{**}$	-55	$1.2 \pm 0.1^{**}$	-50
Rescue Frequency (RF), #/MT/min	6.6 ± 0.5	8.1 ± 0.5	23	$10.4 \pm 1.0^{**}$	58	$10.6 \pm 0.9^{**}$	62
Growth Distance (GD), #/MT/ μm	0.36 ± 0.06	0.40 ± 0.06	11	0.39 ± 0.08	7	$1.00 \pm 0.14^{**}$	173
Shortening Distance (SD), #/MT/ μm	0.35 ± 0.04	$0.69 \pm 0.06^{**}$	95	$1.03 \pm 0.2^{**}$	192	$1.17 \pm 0.14^{**}$	232
Dynamicity	12.0 ± 0.6	$7.5 \pm 0.6^{**}$	-37	$5.9 \pm 0.9^{**}$	-51	$3.0 \pm 0.3^{**}$	-75
Non-dynamic microtubules	5%	6%		17%		44%	

Time dependence for suppression of microtubule dynamic instability in MCF7 cells by 10 nmol/L EpCAM-SPP-DM1

Table 1C

MT Dynamic Instability Parameters	Control	5 hours	% change	10 hours	% change	24 hours	% change
Growth Rate (GR), $\mu\text{m}/\text{min}$	12.9 ± 1.0	$10.5 \pm 0.7^{**}$	-17	$9.9 \pm 0.8^{**}$	-22	$6.4 \pm 0.6^{**}$	-50
Shortening Rate (SR), $\mu\text{m}/\text{min}$	20.0 ± 2.3	$14.4 \pm 1.3^{**}$	-28	$12.3 \pm 1.4^{**}$	-38	$7.8 \pm 1.0^{**}$	-61
% Time Spent Growing (TG)	51	31	-39	26	-50	24	-52
% Time Spent Shortening (TS)	26	21	-21	11	-56	5	-82
% Time Spent Attenuated (TA)	23	48	111	63	176	71	211
Catastrophe Frequency (CF), $\#/\text{MT}/\text{min}$	2.5 ± 0.3	$1.9 \pm 0.1^{*}$	-25	$1.2 \pm 0.1^{**}$	-51	$0.6 \pm 0.1^{**}$	-75
Rescue Frequency (RF), $\#/\text{MT}/\text{min}$	6.6 ± 0.5	7.1 ± 0.5	9	$9.6 \pm 0.7^{**}$	46	$10.9 \pm 1.2^{*}$	67
Growth Distance (GD), $\#/\text{MT}/\mu\text{m}$	0.36 ± 0.06	$0.66 \pm 0.09^{*}$	79	$0.75 \pm 0.10^{**}$	104	0.95 ± 0.35	160
Shortening Distance (SD), $\#/\text{MT}/\mu\text{m}$	0.35 ± 0.04	$0.63 \pm 0.06^{**}$	79	$1.08 \pm 0.10^{**}$	207	$1.70 \pm 0.26^{**}$	382
Dynamics	12.0 ± 0.6	$6.49 \pm 0.5^{**}$	-46	$4.2 \pm 0.4^{**}$	-65	$2.1 \pm 0.3^{**}$	-83
Non-dynamic microtubules	5%	20%		42%		38%	

NOTE: For (A) cells were incubated for 5 h with maytansine or S-methyl DM1 at G2/M arrest 1xIC50 concentrations (310 pmol/L and 340 pmol/L correspondingly) prior to time-lapse microscopy. For (B) EpCAM-SMCC-DM1 and (C) EpCAM-SPP-DM1, cells were incubated with 10 nmol/L of AMCF for the indicated period of time prior to time-lapse microscopy. Results presented are average values $\pm$ SE as well as the corresponding % of change from control. Values with ** are significantly different from control at $\geq 99\%$ confidence interval and values with * are significantly different from control at $\geq 95\%$ confidence interval by Student's t-test. Values for percentage of time spent in growth, shortening and attenuation were calculated for the entire population of microtubules and, thus, the confidence intervals for these parameters cannot be computed.